Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Escherichia Coli Infections-Pipeline Review, H1 2015

Escherichia Coli Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Escherichia Coli Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Escherichia Coli Infections-Pipeline Review, H1 2015', provides an overview of the Escherichia Coli Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Escherichia Coli Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Escherichia Coli Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Escherichia Coli Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Escherichia Coli Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Escherichia Coli Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Escherichia Coli Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Escherichia Coli Infections Overview 9

Therapeutics Development 10

Pipeline Products for Escherichia Coli Infections-Overview 10

Pipeline Products for Escherichia Coli Infections-Comparative Analysis 11

Escherichia Coli Infections-Therapeutics under Development by Companies 12

Escherichia Coli Infections-Therapeutics under Investigation by Universities/Institutes 16

Escherichia Coli Infections-Pipeline Products Glance 18

Clinical Stage Products 18

Early Stage Products 19

Escherichia Coli Infections-Products under Development by Companies 20

Escherichia Coli Infections-Products under Investigation by Universities/Institutes 24

Escherichia Coli Infections-Companies Involved in Therapeutics Development 25

Adenium Biotech ApS 25

Arsanis Biosciences GmbH 26

AvidBiotics Corp. 27

Bellus Health Inc. 28

Bioorganic Research and Services S.A. 29

Cellceutix Corporation 30

Chiesi Farmaceutici SpA 31

ConjuGon, Inc. 32

Debiopharm International S.A. 33

Emergent BioSolutions Inc. 34

F. Hoffmann-La Roche Ltd. 35

GangaGen Inc. 36

Genentech, Inc. 37

GlaxoSmithKline Plc 38

Immuron Limited 39

Melinta Therapeutics, Inc 40

Microbiotix, Inc. 41

Mucosis B.V. 42

Nabriva Therapeutics AG 43

Navigen Pharmaceuticals, Inc. 44

Northern Antibiotics Oy 45

Nosopharm SAS 46

NovaBay Pharmaceuticals, Inc. 47

Novabiotics Limited 48

Nymox Pharmaceutical Corporation 49

Pherecydes Pharma SA 50

Phico Therapeutics Limited 51

Procarta Biosystems Ltd 52

Sanofi Pasteur SA 53

Sealife PHARMA GMBH 54

Sequoia Sciences, Inc. 55

Soligenix, Inc. 56

Spider Biotech 57

Syntiron LLC 58

Trana Discovery, Inc. 59

Escherichia Coli Infections-Therapeutics Assessment 60

Assessment by Monotherapy Products 60

Assessment by Combination Products 61

Assessment by Target 62

Assessment by Mechanism of Action 64

Assessment by Route of Administration 66

Assessment by Molecule Type 68

Drug Profiles 70

A-3APO-Drug Profile 70

AA-139-Drug Profile 72

ACE-920-Drug Profile 73

Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections-Drug Profile 74

BNT-006-Drug Profile 75

BXN-112-Drug Profile 76

Debio-1454-Drug Profile 77

Drug for Infectious Diseases-Drug Profile 78

Drugs for Bacterial Infections-Drug Profile 79

dusquetide-Drug Profile 80

EcoXyn-4V-Drug Profile 82

enterotoxigenic escherichia coli vaccine-Drug Profile 83

enterotoxigenic escherichia coli vaccine-Drug Profile 84

Escherichia coli (whole cell) vaccine-Drug Profile 85

Escherichia coli vaccine-Drug Profile 86

ETEC Adhesin-Based Vaccine-Drug Profile 87

ETEC Vaccine-Drug Profile 88

EV-035-Drug Profile 89

extraintestinal pathogenic escherichia coli vaccine-Drug Profile 91

GN snare-Drug Profile 92

GN-4474-Drug Profile 93

IMM-363-Drug Profile 94

INX-201-Drug Profile 95

MBX-2319-Drug Profile 96

MDN-0057-Drug Profile 97

Monoclonal Antibodies for Escherichia Coli Infections-Drug Profile 99

NAB-7061-Drug Profile 100

NAB-739-Drug Profile 102

NAB-741-Drug Profile 103

NOSO-95300-Drug Profile 104

NP-432-Drug Profile 105

NVC-727-Drug Profile 106

NXC-4720-Drug Profile 107

PMX-1278-Drug Profile 108

PMX-1363-Drug Profile 109

PMX-1405-Drug Profile 110

PMX-247-Drug Profile 111

PP-0121-Drug Profile 112

pritoxaximab + setoxaximab-Drug Profile 114

Proteins for Infectious Diseases-Drug Profile 116

PT-4-Drug Profile 117

Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections-Drug Profile 118

RX-05-Drug Profile 119

RXP-873-Drug Profile 120

SB-041-Drug Profile 121

Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections-Drug Profile 122

Shigetec-Drug Profile 123

SLP-0901-Drug Profile 124

SLP-0905-Drug Profile 125

Small Molecule for Gram-Negative Nosocomial Infections-Drug Profile 126

Small Molecule to Inhibit Rns and VirF for Bacterial Infections-Drug Profile 127

Small Molecules for Bacterial Infections-Drug Profile 128

Small Molecules for Bacterial Infections-Drug Profile 129

Small Molecules for Escherichia Coli Infections-Drug Profile 130

Small Molecules for Escherichia coli Infections-Drug Profile 131

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections-Drug Profile 132

Small Molecules to Inhibit 23S Ribosomal RNA for Infections-Drug Profile 133

Small Molecules to Inhibit 30S RNA, Topoisomerases II and IV for Bacterial Infections-Drug Profile 134

Small Molecules to Inhibit RecA for Bacterial Infections-Drug Profile 135

Synthetic Peptide for Oncology and Infectious Disease-Drug Profile 136

Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease-Drug Profile 137

Synthetic Peptides for Escherichia Coli Infections-Drug Profile 138

Escherichia Coli Infections-Recent Pipeline Updates 139

Escherichia Coli Infections-Dormant Projects 146

Escherichia Coli Infections-Discontinued Products 148

Escherichia Coli Infections-Product Development Milestones 149

Featured News & Press Releases 149

Appendix 151

Methodology 151

Coverage 151

Secondary Research 151

Primary Research 151

Expert Panel Validation 151

Contact Us 151

Disclaimer 152

List of Tables

Number of Products under Development for Escherichia Coli Infections, H1 2015 14

Number of Products under Development for Escherichia Coli Infections-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Development, H1 2015 23

Products under Development by Companies, H1 2015 24

Products under Development by Companies, H1 2015 (Contd..1) 25

Products under Development by Companies, H1 2015 (Contd..2) 26

Products under Development by Companies, H1 2015 (Contd..3) 27

Products under Investigation by Universities/Institutes, H1 2015 28

Escherichia Coli Infections-Pipeline by Adenium Biotech ApS, H1 2015 29

Escherichia Coli Infections-Pipeline by Arsanis Biosciences GmbH, H1 2015 30

Escherichia Coli Infections-Pipeline by AvidBiotics Corp., H1 2015 31

Escherichia Coli Infections-Pipeline by Bellus Health Inc., H1 2015 32

Escherichia Coli Infections-Pipeline by Bioorganic Research and Services S.A., H1 2015 33

Escherichia Coli Infections-Pipeline by Cellceutix Corporation, H1 2015 34

Escherichia Coli Infections-Pipeline by Chiesi Farmaceutici SpA, H1 2015 35

Escherichia Coli Infections-Pipeline by ConjuGon, Inc., H1 2015 36

Escherichia Coli Infections-Pipeline by Debiopharm International S.A., H1 2015 37

Escherichia Coli Infections-Pipeline by Emergent BioSolutions Inc., H1 2015 38

Escherichia Coli Infections-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 39

Escherichia Coli Infections-Pipeline by GangaGen Inc., H1 2015 40

Escherichia Coli Infections-Pipeline by Genentech, Inc., H1 2015 41

Escherichia Coli Infections-Pipeline by GlaxoSmithKline Plc, H1 2015 42

Escherichia Coli Infections-Pipeline by Immuron Limited, H1 2015 43

Escherichia Coli Infections-Pipeline by Melinta Therapeutics, Inc, H1 2015 44

Escherichia Coli Infections-Pipeline by Microbiotix, Inc., H1 2015 45

Escherichia Coli Infections-Pipeline by Mucosis B.V., H1 2015 46

Escherichia Coli Infections-Pipeline by Nabriva Therapeutics AG, H1 2015 47

Escherichia Coli Infections-Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 48

Escherichia Coli Infections-Pipeline by Northern Antibiotics Oy, H1 2015 49

Escherichia Coli Infections-Pipeline by Nosopharm SAS, H1 2015 50

Escherichia Coli Infections-Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015 51

Escherichia Coli Infections-Pipeline by Novabiotics Limited, H1 2015 52

Escherichia Coli Infections-Pipeline by Nymox Pharmaceutical Corporation, H1 2015 53

Escherichia Coli Infections-Pipeline by Pherecydes Pharma SA, H1 2015 54

Escherichia Coli Infections-Pipeline by Phico Therapeutics Limited, H1 2015 55

Escherichia Coli Infections-Pipeline by Procarta Biosystems Ltd, H1 2015 56

Escherichia Coli Infections-Pipeline by Sanofi Pasteur SA, H1 2015 57

Escherichia Coli Infections-Pipeline by Sealife PHARMA GMBH, H1 2015 58

Escherichia Coli Infections-Pipeline by Sequoia Sciences, Inc., H1 2015 59

Escherichia Coli Infections-Pipeline by Soligenix, Inc., H1 2015 60

Escherichia Coli Infections-Pipeline by Spider Biotech, H1 2015 61

Escherichia Coli Infections-Pipeline by Syntiron LLC, H1 2015 62

Escherichia Coli Infections-Pipeline by Trana Discovery, Inc., H1 2015 63

Assessment by Monotherapy Products, H1 2015 64

Assessment by Combination Products, H1 2015 65

Number of Products by Stage and Target, H1 2015 67

Number of Products by Stage and Mechanism of Action, H1 2015 69

Number of Products by Stage and Route of Administration, H1 2015 71

Number of Products by Stage and Molecule Type, H1 2015 73

Escherichia Coli Infections Therapeutics-Recent Pipeline Updates, H1 2015 143

Escherichia Coli Infections-Dormant Projects, H1 2015 150

Escherichia Coli Infections-Dormant Projects (Contd..1), H1 2015 151

Escherichia Coli Infections-Discontinued Products, H1 2015 152

List of Figures

Number of Products under Development for Escherichia Coli Infections, H1 2015 14

Number of Products under Development for Escherichia Coli Infections-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Products, H1 2015 23

Assessment by Monotherapy Products, H1 2015 64

Number of Products by Top 10 Targets, H1 2015 66

Number of Products by Stage and Top 10 Targets, H1 2015 66

Number of Products by Top 10 Mechanism of Actions, H1 2015 68

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 68

Number of Products by Top 10 Routes of Administration, H1 2015 70

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 70

Number of Products by Top 10 Molecule Types, H1 2015 72

Number of Products by Stage and Top 10 Molecule Types, H1 2015 72

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adenium Biotech ApS

Arsanis Biosciences GmbH

AvidBiotics Corp.

Bellus Health Inc.

Bioorganic Research and Services S.A.

Cellceutix Corporation

Chiesi Farmaceutici SpA

ConjuGon, Inc.

Debiopharm International S.A.

Emergent BioSolutions Inc.

F. Hoffmann-La Roche Ltd.

GangaGen Inc.

Genentech, Inc.

GlaxoSmithKline Plc

Immuron Limited

Melinta Therapeutics, Inc

Microbiotix, Inc.

Mucosis B.V.

Nabriva Therapeutics AG

Navigen Pharmaceuticals, Inc.

Northern Antibiotics Oy

Nosopharm SAS

NovaBay Pharmaceuticals, Inc.

Novabiotics Limited

Nymox Pharmaceutical Corporation

Pherecydes Pharma SA

Phico Therapeutics Limited

Procarta Biosystems Ltd

Sanofi Pasteur SA

Sealife PHARMA GMBH

Sequoia Sciences, Inc.

Soligenix, Inc.

Spider Biotech

Syntiron LLC

Trana Discovery, Inc.

Escherichia Coli Infections Therapeutic Products under Development, Key Players in Escherichia Coli Infections Therapeutics, Escherichia Coli Infections Pipeline Overview, Escherichia Coli Infections Pipeline, Escherichia Coli Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com